The spindle assembly checkpoint is a therapeutic vulnerability of CDK4/6 inhibitor–resistant ER(+) breast cancer with mitotic aberrations

Inhibitors of cyclin-dependent kinases 4 and 6 (CDK4/6i) are standard first-line treatments for metastatic ER(+) breast cancer. However, acquired resistance to CDK4/6i invariably develops, and the molecular phenotypes and exploitable vulnerabilities associated with resistance are not yet fully chara...

Descripción completa

Detalles Bibliográficos
Autores principales: Soria-Bretones, Isabel, Thu, Kelsie L., Silvester, Jennifer, Cruickshank, Jennifer, El Ghamrasni, Samah, Ba-alawi, Wail, Fletcher, Graham C., Kiarash, Reza, Elliott, Mitchell J., Chalmers, Jordan J., Elia, Andrea C., Cheng, Albert, Rose, April A. N., Bray, Mark R., Haibe-Kains, Benjamin, Mak, Tak W., Cescon, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2022
Materias:
Biomedicine and Life Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451148/
https://www.ncbi.nlm.nih.gov/pubmed/36070391
http://dx.doi.org/10.1126/sciadv.abq4293

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9451148/
https://www.ncbi.nlm.nih.gov/pubmed/36070391
http://dx.doi.org/10.1126/sciadv.abq4293

Ejemplares similares